Entresto

Entresto Indications/Uses

sacubitril + valsartan

Manufacturer:

Novartis

Distributor:

Zuellig Pharma
Full Prescribing Info
Indications/Uses
Entresto is indicated to reduce the risk of cardiovascular mortality and morbidity in adult patients with systolic heart failure (NYHA Class II-IV, LVEF ≤40%).
Entresto is administered in combination with other heart failure therapies (e.g. betablockers, diuretics and mineralocorticoid antagonists) as appropriate, in place of an ACE inhibitor or other ARB.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in